The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

The Institute for Clinical and Economic Review (ICER) has published its final report on Spravato (esketamine) and says the drug would need to be between 25% and 52% cheaper to meet its value ...

Spravato (esketamine) has possible interactions with alcohol, some other drugs, and certain supplements. Examples include Adderall and benzodiazepines such as clonazepam (Klonopin). Talk with your ...

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...

Spravato is approved as an adjunctive therapy administered by a nasal spray and is based on esketamine, a form of the drug ketamine, an anaesthetic commonly used illegally for recreational purposes.

So SPRAVATO is indicated for treatment resistant depression. It is esketamine. It's a single enantiomer of ketamine. It's an intranasally administered compound. It was approved in 2019 for ...

Stella Mental Health Westmont is a top depression and anxiety clinic near Chicago that offers comprehensive mental health treatments like Spravato (esketamine) therapy, ketamine infusion ...

The analyst equates COMP360 to Spravato 2.0. Johnson & Johnson’s JNJ Spravato (esketamine) is a nasal spray for TRD and major depressive disorder (MDD), selling over ~$1 billion annually.

Stella Mental Health Westmont is a top depression and anxiety clinic near Chicago that offers comprehensive mental health treatments like Spravato (esketamine) therapy, ketamine infusion ...